• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Marksans Pharma receives GMP certificate

financialexpressMay 02, 2017

Tag: GMP , Marksans

TGA, Department of Health, Australia issued the certificate for its Verna facility in Goa

Drug firm Marksans Pharma has received certificate of Good Manufacturing practice (GMP) compliance from the Australian drugs and devices regulator for its Verna facility in Goa.

The company has received Certificate of GMP Compliance of a Manufacturer from Therapeutic Goods Administration (TGA), Department of Health, Australia for its manufacturing facility at Verna in Goa, Marksans Pharma said in a filing to BSE.

Previous:England's Cancer Drugs Fund 'failed to deliver meaningful value to patients and society'

Next:Sun Pharma Science Foundation recognises Indian scientists and young research scholars

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Marksans Pharma receives GMP certificate | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

99% up GMP DMF Isocorydine 475-67-2

99% up GMP DMF Isocorydine 475-67-2
Toremifene citrate for Anticancer in China 99% GMP

Toremifene citrate for Anticancer in China 99% GMP
99% up by HPLC USP GMP DMF Posaconazole 171228-49-2

99% up by HPLC USP GMP DMF Posaconazole 171228-49-2
99% up GMP DMF Potassium clavulanate 61177-45-5

99% up GMP DMF Potassium clavulanate 61177-45-5
99% up GMP DMF Creatine Monohydrate Creatine phosphate 67-07-2

99% up GMP DMF Creatine Monohydrate Creatine phosphate 67-07-2
99% up GMP DMF Maxacalcitol 103909-75-7

99% up GMP DMF Maxacalcitol 103909-75-7
factory supply GMP,DMF Benzylpenicillin Sodium / Penicillin G sodium CAS NO.69-57-8

factory supply GMP,DMF Benzylpenicillin Sodium / Penicillin G sodium CAS NO.69-57-8
99% up GMP DMF Glucuronic acid monosodium salt 7182-77-6

99% up GMP DMF Glucuronic acid monosodium salt 7182-77-6
99% up GMP DMF Isotretinoin 4759-48-2

99% up GMP DMF Isotretinoin 4759-48-2
99% up GMP DMF Inosine 58-63-9

99% up GMP DMF Inosine 58-63-9

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service